Argenx

Company snapshot

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.

• 32 active pipeline program(s) linked via ClinicalTrials.gov.
• 32 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Argenx. Not investment advice.

• Peer + 0 momentum

  Dianthus Therapeutics, Inc

  TA overlap score 31.2

Recent activity

Latest pipeline, patent, and corporate events for Argenx.

1. Jun 8, 2026 Clinical update

   ARGX-119-2303 — Phase 2

2. Jun 8, 2026 Clinical update

   ARGX-117-2402 — Phase 3

3. Jun 8, 2026 Clinical update

   ARGX-117-2301 — Phase 2

4. Jun 8, 2026 Clinical update

   ARGX-113-2405 — Phase 1

5. Jun 8, 2026 Clinical update

   ARGX-113-2315 — Phase 3

View all clinical trial activity →

• What is Argenx?

  argenx is a pharma organization headquartered in GENT, BE. Primary therapeutic focus areas include Generalized Myasthenia Gravis, Chronic inflammatory demyelinating polyneuropathy (CIDP), Bullous Pemphigoid, Thyroid Eye Disease (TED), Multifocal Motor Neuropathy. NovaPharmaNews l

• Is Argenx publicly traded?

  Argenx appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Argenx develop or market?

  We link 16 drug profile(s) where Argenx is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/argenx#company-drugs.

• What are the latest developments for Argenx?

  In the last 12 months our linked public records show 32 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Argenx focus on?

  Argenx focuses on Generalized Myasthenia Gravis, Chronic inflammatory demyelinating polyneuropathy (CIDP), Bullous Pemphigoid based on our analysis of their pipeline programs and drug development activities.